XENON PHARMACEUTICALS INC. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
XENON PHARMACEUTICALS INC. (XENE) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $132.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- XENON PHARMACEUTICALS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was -$130.00K.
- XENON PHARMACEUTICALS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was -$64.00K.
- XENON PHARMACEUTICALS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$367.00K, a 722.03% decline year-over-year.
- XENON PHARMACEUTICALS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was $59.00K, a 79.86% decline year-over-year.
- XENON PHARMACEUTICALS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $458.00K.
- XENON PHARMACEUTICALS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$1.67M, a 544.68% decline from fiscal 2023.
- XENON PHARMACEUTICALS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was $376.00K.
- XENON PHARMACEUTICALS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$2.48M.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | $132.00K 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | -$130.00K 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $458.00K 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $562.00K 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | $568.00K 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | -$64.00K 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$1.67M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | -$515.00K 10-Q · filed 2025-11-03 | |||
| 2024-06-30 | -$569.00K 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | -$367.00K 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $376.00K 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $130.00K 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | $418.00K 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $59.00K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$2.48M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | -$3.30M 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | -$600.00K 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | $293.00K 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | -$592.00K 10-K · filed 2024-02-29 | |||
| 2021-09-30 | -$661.00K 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | -$214.00K 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | $67.00K 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | -$593.00K 10-K · filed 2023-03-01 | |||
| 2020-09-30 | -$372.00K 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | -$459.00K 10-Q · filed 2021-08-11 | |||
| 2020-03-31 | -$725.00K 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | $406.00K 10-K · filed 2021-03-01 | |||
| 2019-09-30 | $222.00K 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $326.00K 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $67.00K 10-Q/A · filed 2020-05-26 | |||
| 2018-12-31 | -$612.00K 10-K · filed 2020-03-09 | |||
| 2018-09-30 | -$168.00K 10-Q · filed 2019-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |